{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:23:36Z","timestamp":1779337416942,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00431-021-04294-7","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T12:02:43Z","timestamp":1636977763000},"page":"1159-1165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Serum albumin level is associated with mycophenolic acid concentration in children with idiopathic nephrotic syndrome"],"prefix":"10.1007","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-4293","authenticated-orcid":false,"given":"Tatsuya","family":"Nishimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hibino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Kitagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sotaro","family":"Yuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Kasagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"4294_CR1","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1097\/01.tp.0000186957.32801.c0","volume":"80","author":"R Ettenger","year":"2005","unstructured":"Ettenger R, Sarwal MM (2005) Mycophenolate mofetil in pediatric renal transplantation. Transplantation 80:S201\u2013S210","journal-title":"Transplantation"},{"key":"4294_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/0961203308094999","volume":"18","author":"F Falcini","year":"2009","unstructured":"Falcini F, Capannini S, Martini G, La Torre F, Vitale A, Mangiantini F, Nacci F, Cerinic MM, Cimaz R, Zulian F (2009) Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 18:139\u2013143","journal-title":"Lupus"},{"key":"4294_CR3","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00467-018-3970-y","volume":"33","author":"U Querfeld","year":"2018","unstructured":"Querfeld U, Weber LT (2018) Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol 33:2253\u20132265","journal-title":"Pediatr Nephrol"},{"key":"4294_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","volume":"22","author":"S Fujinaga","year":"2007","unstructured":"Fujinaga S, Ohtomo Y, Umino D, Takemoto M, Shimizu T, Yamashiro Y, Kaneko K (2007) A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatr Nephrol 22:71\u201376","journal-title":"Pediatr Nephrol"},{"key":"4294_CR5","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10157-016-1319-z","volume":"21","author":"K Kikunaga","year":"2017","unstructured":"Kikunaga K, Ishikura K, Terano C et al (2017) High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study). Clin Exp Nephrol 21:651\u2013657","journal-title":"Clin Exp Nephrol"},{"key":"4294_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","volume":"392","author":"DG Noone","year":"2018","unstructured":"Noone DG, Iijima K, Parekh R (2018) Idiopathic nephrotic syndrome in children. Lancet 392:61\u201374","journal-title":"Lancet"},{"key":"4294_CR7","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1093\/ndt\/gfr572","volume":"27","author":"J Gellermann","year":"2012","unstructured":"Gellermann J, Ehrich JHH, Querfeld U (2012) Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 27:1970\u20131978","journal-title":"Nephrol Dial Transplant"},{"key":"4294_CR8","doi-asserted-by":"crossref","unstructured":"Nikibakhsh AA, Mahmoodzadeh H, Karamyyar M, Hejazi S, Noroozi M, Macooie AA (2011) Treatment of steroid and cyclosporine-resistant idiopathic nephrotic syndrome in children. Int J Nephrol 2011:930965","DOI":"10.4061\/2011\/930965"},{"key":"4294_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ped.12498","volume":"57","author":"S Hibino","year":"2015","unstructured":"Hibino S, Uemura O, Nagai T, Yamakawa S, Iwata N, Ito H, Nakano M, Tanaka K (2015) Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol. Pediatr Int 57:85\u201391","journal-title":"Pediatr Int"},{"key":"4294_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.clinthera.2008.04.014","volume":"30","author":"DR Kuypers","year":"2008","unstructured":"Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y (2008) Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 30:673\u2013683","journal-title":"Clin Ther"},{"key":"4294_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/FTD.0000000000000258","volume":"38","author":"\u00c1 Hackl","year":"2016","unstructured":"Hackl \u00c1, Cseprek\u00e1l O, Gessner M, Liebau MC, Habbig S, Ehren R, M\u00fcller C, Taylan C, D\u00f6tsch J, Weber LT (2016) Mycophenolate mofetil therapy in children with idiopathic nephrotic syndrome: does therapeutic drug monitoring make a difference? Ther Drug Monit 38:274\u2013279","journal-title":"Ther Drug Monit"},{"key":"4294_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/bs.acc.2016.04.001","volume":"76","author":"A Dasgupta","year":"2016","unstructured":"Dasgupta A (2016) Therapeutic drug monitoring of mycophenolic acid. Adv Clin Chem 76:165\u2013184","journal-title":"Adv Clin Chem"},{"key":"4294_CR13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/00007691-200406000-00011","volume":"26","author":"BA Atcheson","year":"2004","unstructured":"Atcheson BA, Taylor PJ, Kirkpatrick CM, Duffull SB, Mudge DW, Pillans PI, Johnson DW, Tett SE (2004) Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit 26:284\u2013286","journal-title":"Ther Drug Monit"},{"key":"4294_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10928-009-9136-6","volume":"36","author":"BC de Winter","year":"2009","unstructured":"de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA (2009) Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn 36:541\u2013564","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"4294_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.dmpk.2015.10.004","volume":"30","author":"K Yoshimura","year":"2015","unstructured":"Yoshimura K, Yano I, Kawanishi M, Nakagawa S, Yonezawa A, Matsubara K (2015) Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: evaluation of protein binding effects using the modeling and simulation approach. Drug Metab Pharmacokinet 30:441\u2013448","journal-title":"Drug Metab Pharmacokinet"},{"key":"4294_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00228-018-2599-x","volume":"75","author":"P Luszczynska","year":"2019","unstructured":"Luszczynska P, Pawinski T, Kunicki PK, Durlik M, Augustyniak-Bartosik H, Hurkacz M (2019) Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. Eur J Clin Pharmacol 75:371\u2013379","journal-title":"Eur J Clin Pharmacol"},{"key":"4294_CR17","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1016\/j.transproceed.2012.09.063","volume":"44","author":"JM Vergara Chozas","year":"2012","unstructured":"Vergara Chozas JM, S\u00e1ez-Benito Godino A, Zopeque Garc\u00eda N, Garc\u00eda Pinte\u00f1o S, Joumady I, Carrasco Garc\u00eda C, Vara Gil F (2012) Analytical validation of a homogeneous immunoassay for determination of mycophenolic acid in human plasma. Transplant Proc 44:2669\u20132672","journal-title":"Transplant Proc"},{"key":"4294_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0009-9120(03)00011-0","volume":"36","author":"AW Butch","year":"2003","unstructured":"Butch AW, Fukuchi AM (2003) Evaluation of a new pretreatment reagent for use with the EMIT 2000 cyclosporine assay. Clin Biochem 36:313\u2013316","journal-title":"Clin Biochem"},{"key":"4294_CR19","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1007\/s10157-013-0856-y","volume":"18","author":"O Uemura","year":"2014","unstructured":"Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, Fujita N, Akioka Y, Kaneko T, Honda M (2014) Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol 18:626\u2013633","journal-title":"Clin Exp Nephrol"},{"key":"4294_CR20","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10157-017-1460-3","volume":"22","author":"O Uemura","year":"2018","unstructured":"Uemura O, Ishikura K, Gotoh Y, Honda M (2018) Creatinine-based estimated glomerular filtration rate for children younger than 2 years. Clin Exp Nephrol 22:483\u2013484","journal-title":"Clin Exp Nephrol"},{"key":"4294_CR21","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","volume":"34","author":"RE Bullingham","year":"1998","unstructured":"Bullingham RE, Nicholls AJ, Kamm BR (1998) Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429\u2013455","journal-title":"Clin Pharmacokinet"},{"key":"4294_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00003088-197601010-00003","volume":"1","author":"R Gugler","year":"1976","unstructured":"Gugler R, Azarnoff DL (1976) Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet 1:25\u201335","journal-title":"Clin Pharmacokinet"},{"key":"4294_CR23","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/clinchem\/41.7.1011","volume":"41","author":"I Nowak","year":"1995","unstructured":"Nowak I, Shaw LM (1995) Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41:1011\u20131017","journal-title":"Clin Chem"},{"key":"4294_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1681\/ASN.V133759","volume":"13","author":"LT Weber","year":"2002","unstructured":"Weber LT, Shipkova M, Armstrong VW, Wagner N, Sch\u00fctz E, Mehls O, Zimmerhackl LB, Oellerich M, T\u00f6nshoff B (2002) The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759\u2013768","journal-title":"J Am Soc Nephrol"},{"key":"4294_CR25","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1681\/ASN.2005101070","volume":"17","author":"RM van Hest","year":"2006","unstructured":"van Hest RM, Mathot RAA, Pescovitz MD, Gordon R, Mamelok RD, van Gelder T (2006) Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol 17:871\u2013880","journal-title":"J Am Soc Nephrol"},{"key":"4294_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10157-016-1267-7","volume":"21","author":"S Hibino","year":"2017","unstructured":"Hibino S, Nagai T, Yamakawa S, Ito H, Tanaka K, Uemura O (2017) Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. Clin Exp Nephrol 21:152\u2013158","journal-title":"Clin Exp Nephrol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-021-04294-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-021-04294-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T16:03:21Z","timestamp":1646409801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-021-04294-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4294"],"URL":"https:\/\/doi.org\/10.1007\/s00431-021-04294-7","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]},"assertion":[{"value":"8 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the ethics board of Aichi Children\u2019s Health and Medical Center (12 July 2019\/No. 2019018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Because only existing data were used, the requirement for informed consent was waived, but information about this research and a means to opt out were provided.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"As with the consent to participate, information and a means to opt out were provided.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}